- Altos Labs – a $3 billion biotech startup backed by Jeff Bezos – is on a mission to restore cell health and reverse diseases by rejuvenating cells labiotech.eu. It launched in 2022 with a dream of extending healthy human lifespan.
- Not about “cheating death”: Altos’s president Hans Bishop insists the focus is on extending “healthspan” (years of healthy life), with any longevity gains merely an “accidental consequence” fightaging.org. The company emphasizes improving life quality over pursuing immortality.
- Unprecedented talent & funding: Altos assembled a “dream team” of scientists – including Nobel laureate Shinya Yamanaka – by offering academic freedom and industry-level resources. Led by former GSK executive Hal Barron as CEO, and co-founded by biotech veterans Richard Klausner and Hans Bishop, Altos attracted $3 billion from prominent investors (Bezos, Yuri Milner, Arch Ventures) labiotech.eu en.wikipedia.org, making it one of the best-funded startups in biotech history.
- Racing a booming longevity industry: Altos Labs is part of a broader anti-aging biotech boom. Alphabet’s Calico Labs (launched 2013) was a pioneer, and newer startups like Retro Biosciences and Loyal have joined the fray – all aiming to extend healthy lifespan via cutting-edge science and drawing investments from Silicon Valley billionaires businessinsider.com 1 .
- Innovations in “rejuvenation” science: Altos and its peers are leveraging breakthroughs like partial cellular reprogramming – using Yamanaka factors to reset adult cells to a youthful state – which has shown promise in animals labiotech.eu labiotech.eu. Other approaches include senolytic drugs to clear aged “zombie” cells and gene therapies, all targeting aging at its biological roots.
- Early results signal hope: In 2024, Altos scientists published a landmark study demonstrating that partial reprogramming extended the lifespan of mice and improved health markers labiotech.eu. This evidence that aging may be reversible has been hailed as a major step toward translating rejuvenation technologies to humans.
- Competition and collaboration: Companies like Retro Biosciences (funded by OpenAI’s Sam Altman) aim to add 10+ years to human life through cell reprogramming and autophagy, planning their first clinical trials and reportedly seeking $1 billion for next steps labiotech.eu labiotech.eu. Loyal, which has raised over $125 million, is developing drugs to extend dogs’ lifespans as a springboard to human applications – and expects to launch the first FDA-approved longevity drug for pets by 2025 2 3
Inside Altos Labs: Jeff Bezos’s $3 Billion Bet to Reverse Aging
Stock Market Today
Robinhood stock jumps 14% as bitcoin rebounds — what to watch before HOOD earnings
Robinhood shares surged 13.95% to $82.82 Friday after bitcoin rebounded above $70,000, snapping a four-day slide. The stock remains down 17% from Jan. 30. Chief Legal Officer Daniel Gallagher sold 10,000 shares earlier in the week. Robinhood reports quarterly results Tuesday after the bell.
Alphabet stock drops for a fourth straight day as AI spending jitters linger
Alphabet shares fell 2.53% to $322.86 Friday, marking a fourth straight decline as investors questioned heavy AI-related spending. The Nasdaq slipped Thursday after Alphabet detailed up to $185 billion in capex, while the Dow and S&P 500 rose Friday on chipmaker gains. U.S. markets reopen Monday, with attention on Alphabet’s outlook and upcoming jobs and inflation data.
BBAI stock jumps 16% into BigBear.ai share-vote week — what to watch next
BigBear.ai Holdings shares surged 15.7% Friday to $4.72 ahead of a key shareholder vote on doubling authorized shares to 1 billion. Options trading was heavy, with a put/call ratio of 0.19. The company recently announced deals in AI customs technology and a partnership with Abu Dhabi’s AD Ports Group. The special meeting is set for Feb. 18, with online voting open until late Feb. 17.
Strategy (MSTR) stock price whipsaws after $12.4 billion loss as bitcoin steadies — what to watch next week
Strategy Inc shares jumped 26.1% Friday to $134.93 after plunging 17.1% the day before, following a $12.4 billion quarterly loss tied to bitcoin price swings. The company held 713,502 bitcoins as of Feb. 1 at a cost of $54.26 billion. Bitcoin hovered near $69,000 Saturday. Strategy set up a $2.25 billion reserve to cover dividends and interest.
